KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Long-Term Investments: 2017-2025

Historic Long-Term Investments for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $2.1 billion.

  • Moderna's Long-Term Investments fell 8.22% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 8.22%. This contributed to the annual value of $2.5 billion for FY2024, which is 46.68% down from last year.
  • As of Q3 2025, Moderna's Long-Term Investments stood at $2.1 billion, which was down 9.73% from $2.4 billion recorded in Q2 2025.
  • Moderna's Long-Term Investments' 5-year high stood at $10.2 billion during Q2 2022, with a 5-year trough of $468.0 million in Q1 2021.
  • For the 3-year period, Moderna's Long-Term Investments averaged around $3.7 billion, with its median value being $2.5 billion (2024).
  • In the last 5 years, Moderna's Long-Term Investments soared by 1,859.62% in 2022 and then crashed by 61.90% in 2024.
  • Over the past 5 years, Moderna's Long-Term Investments (Quarterly) stood at $6.8 billion in 2021, then climbed by 21.55% to $8.3 billion in 2022, then tumbled by 43.77% to $4.7 billion in 2023, then tumbled by 46.68% to $2.5 billion in 2024, then decreased by 8.22% to $2.1 billion in 2025.
  • Its Long-Term Investments stands at $2.1 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.4 billion for Q1 2025.